(ZTS) Zoetis - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US98978V1035
Vaccines, Parasiticides, Diagnostics, Dermatology, Anti-Infectives
Dividends
| Dividend Yield | 1.70% |
| Yield on Cost 5y | 1.31% |
| Yield CAGR 5y | 21.23% |
| Payout Consistency | 100.0% |
| Payout Ratio | 32.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 26.6% |
| Value at Risk 5%th | 40.2% |
| Relative Tail Risk | -7.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.35 |
| Alpha | -44.25 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.629 |
| Beta | 0.625 |
| Beta Downside | 0.529 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.89% |
| Mean DD | 12.35% |
| Median DD | 11.00% |
Description: ZTS Zoetis December 03, 2025
Zoetis Inc. (NYSE: ZTS) develops, manufactures, and markets a broad portfolio of animal-health products-including medicines, vaccines, diagnostics, biodevices, genetic tests, and precision-health solutions-for livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses). Its offerings span parasiticides, anti-infectives, dermatology, pain-management, and point-of-care diagnostics, and it sells primarily to veterinarians, livestock producers, and pet owners. The company also partners with Blacksmith Medicines to explore novel animal-health antibiotics.
Key recent data points: • FY 2023 revenue reached $7.6 billion, with a 9 % YoY increase driven by strong growth in companion-animal vaccines and livestock pharmaceuticals. • The global animal-health market is projected to expand at a CAGR of ~5 % through 2028, underpinned by rising protein demand and higher pet-care spending. • Zoetis’s 2024 guidance anticipates a 6-7 % earnings-per-share growth, supported by its expanding precision-health platform and cost-efficiency initiatives in manufacturing.
For a deeper, data-driven look at ZTS’s valuation and risk profile, you may find ValueRay’s analyst tools helpful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (2.65b TTM) > 0 and > 6% of Revenue (6% = 563.8m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA -1.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 50.82% (prev 50.04%; Δ 0.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 2.92b > Net Income 2.65b (YES >=105%, WARN >=100%) |
| Net Debt (5.19b) to EBITDA (4.05b) ratio: 1.28 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (443.2m) change vs 12m ago -2.27% (target <= -2.0% for YES) |
| Gross Margin 70.63% (prev 68.49%; Δ 2.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.67% (prev 63.75%; Δ -0.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.42 (EBITDA TTM 4.05b / Interest Expense TTM 231.0m) >= 6 (WARN >= 3) |
Altman Z'' 7.99
| (A) 0.32 = (Total Current Assets 6.58b - Total Current Liabilities 1.81b) / Total Assets 15.16b |
| (B) 0.90 = Retained Earnings (Balance) 13.59b / Total Assets 15.16b |
| warn (B) unusual magnitude: 0.90 — check mapping/units |
| (C) 0.24 = EBIT TTM 3.56b / Avg Total Assets 14.76b |
| (D) 1.31 = Book Value of Equity 12.78b / Total Liabilities 9.76b |
| Total Rating: 7.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 88.49
| 1. Piotroski 6.50pt |
| 2. FCF Yield 3.64% |
| 3. FCF Margin 23.84% |
| 4. Debt/Equity 1.35 |
| 5. Debt/Ebitda 1.28 |
| 6. ROIC - WACC (= 17.41)% |
| 7. RoE 53.56% |
| 8. Rev. Trend 92.34% |
| 9. EPS Trend 85.84% |
What is the price of ZTS shares?
As of December 12, 2025, the stock is trading at USD 117.66 with a total of 6,150,112 shares traded.
Over the past week, the price has changed by -2.28%, over one month by -2.05%, over three months by -21.61% and over the past year by -32.70%.
Over the past week, the price has changed by -2.28%, over one month by -2.05%, over three months by -21.61% and over the past year by -32.70%.
Is ZTS a buy, sell or hold?
Zoetis has received a consensus analysts rating of 4.26.
Therefore, it is recommended to buy ZTS.
- Strong Buy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ZTS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 170 | 44.5% |
| Analysts Target Price | 170 | 44.5% |
| ValueRay Target Price | 112.1 | -4.7% |
ZTS Fundamental Data Overview December 03, 2025
Market Cap USD = 56.40b (56.40b USD * 1.0 USD.USD)
P/E Trailing = 21.4226
P/E Forward = 19.4932
P/S = 6.0014
P/B = 10.4646
P/EG = 2.4061
Beta = 0.962
Revenue TTM = 9.40b USD
EBIT TTM = 3.56b USD
EBITDA TTM = 4.05b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last fiscal year)
Debt = 7.27b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.19b USD (from netDebt column, last quarter)
Enterprise Value = 61.58b USD (56.40b + Debt 7.27b - CCE 2.08b)
Interest Coverage Ratio = 15.42 (Ebit TTM 3.56b / Interest Expense TTM 231.0m)
FCF Yield = 3.64% (FCF TTM 2.24b / Enterprise Value 61.58b)
FCF Margin = 23.84% (FCF TTM 2.24b / Revenue TTM 9.40b)
Net Margin = 28.21% (Net Income TTM 2.65b / Revenue TTM 9.40b)
Gross Margin = 70.63% ((Revenue TTM 9.40b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 71.54% (prev 72.28%)
Tobins Q-Ratio = 4.06 (Enterprise Value 61.58b / Total Assets 15.16b)
Interest Expense / Debt = 0.80% (Interest Expense 58.0m / Debt 7.27b)
Taxrate = 18.71% (166.0m / 887.0m)
NOPAT = 2.90b (EBIT 3.56b * (1 - 18.71%))
Current Ratio = 3.64 (Total Current Assets 6.58b / Total Current Liabilities 1.81b)
Debt / Equity = 1.35 (Debt 7.27b / totalStockholderEquity, last quarter 5.40b)
Debt / EBITDA = 1.28 (Net Debt 5.19b / EBITDA 4.05b)
Debt / FCF = 2.32 (Net Debt 5.19b / FCF TTM 2.24b)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.49% (Net Income 2.65b / Total Assets 15.16b)
RoE = 53.56% (Net Income TTM 2.65b / Total Stockholder Equity 4.95b)
RoCE = 29.64% (EBIT 3.56b / Capital Employed (Equity 4.95b + L.T.Debt 7.07b))
RoIC = 24.85% (NOPAT 2.90b / Invested Capital 11.65b)
WACC = 7.44% (E(56.40b)/V(63.67b) * Re(8.32%) + D(7.27b)/V(63.67b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.85%
[DCF Debug] Terminal Value 79.88% ; FCFE base≈2.27b ; Y1≈2.67b ; Y5≈4.09b
Fair Price DCF = 150.8 (DCF Value 66.47b / Shares Outstanding 440.7m; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: 85.84 | EPS CAGR: 15.20% | SUE: 0.96 | # QB: 3
Revenue Correlation: 92.34 | Revenue CAGR: 5.45% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.57 | Chg30d=-0.010 | Revisions Net=-5 | Analysts=9
EPS next Year (2026-12-31): EPS=6.81 | Chg30d=-0.067 | Revisions Net=-10 | Growth EPS=+7.4% | Growth Revenue=+5.3%
P/E Trailing = 21.4226
P/E Forward = 19.4932
P/S = 6.0014
P/B = 10.4646
P/EG = 2.4061
Beta = 0.962
Revenue TTM = 9.40b USD
EBIT TTM = 3.56b USD
EBITDA TTM = 4.05b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last fiscal year)
Debt = 7.27b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.19b USD (from netDebt column, last quarter)
Enterprise Value = 61.58b USD (56.40b + Debt 7.27b - CCE 2.08b)
Interest Coverage Ratio = 15.42 (Ebit TTM 3.56b / Interest Expense TTM 231.0m)
FCF Yield = 3.64% (FCF TTM 2.24b / Enterprise Value 61.58b)
FCF Margin = 23.84% (FCF TTM 2.24b / Revenue TTM 9.40b)
Net Margin = 28.21% (Net Income TTM 2.65b / Revenue TTM 9.40b)
Gross Margin = 70.63% ((Revenue TTM 9.40b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 71.54% (prev 72.28%)
Tobins Q-Ratio = 4.06 (Enterprise Value 61.58b / Total Assets 15.16b)
Interest Expense / Debt = 0.80% (Interest Expense 58.0m / Debt 7.27b)
Taxrate = 18.71% (166.0m / 887.0m)
NOPAT = 2.90b (EBIT 3.56b * (1 - 18.71%))
Current Ratio = 3.64 (Total Current Assets 6.58b / Total Current Liabilities 1.81b)
Debt / Equity = 1.35 (Debt 7.27b / totalStockholderEquity, last quarter 5.40b)
Debt / EBITDA = 1.28 (Net Debt 5.19b / EBITDA 4.05b)
Debt / FCF = 2.32 (Net Debt 5.19b / FCF TTM 2.24b)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.49% (Net Income 2.65b / Total Assets 15.16b)
RoE = 53.56% (Net Income TTM 2.65b / Total Stockholder Equity 4.95b)
RoCE = 29.64% (EBIT 3.56b / Capital Employed (Equity 4.95b + L.T.Debt 7.07b))
RoIC = 24.85% (NOPAT 2.90b / Invested Capital 11.65b)
WACC = 7.44% (E(56.40b)/V(63.67b) * Re(8.32%) + D(7.27b)/V(63.67b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.85%
[DCF Debug] Terminal Value 79.88% ; FCFE base≈2.27b ; Y1≈2.67b ; Y5≈4.09b
Fair Price DCF = 150.8 (DCF Value 66.47b / Shares Outstanding 440.7m; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: 85.84 | EPS CAGR: 15.20% | SUE: 0.96 | # QB: 3
Revenue Correlation: 92.34 | Revenue CAGR: 5.45% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.57 | Chg30d=-0.010 | Revisions Net=-5 | Analysts=9
EPS next Year (2026-12-31): EPS=6.81 | Chg30d=-0.067 | Revisions Net=-10 | Growth EPS=+7.4% | Growth Revenue=+5.3%
Additional Sources for ZTS Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle